Dr. Janus on the Role of Moxetumomab Pasudotox in Hairy Cell Leukemia
October 24th 2019
Agnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.